Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHua WangCentral South UniversityYLYu LiHarbin University of Science and TechnologyJZJie ZhaXiamen University

Discussion

Loading...

Member takes

Overview

Clinical trial shows 81.8% overall response in treatment-naïve marginal zone lymphoma, highlighting safety and efficacy of orelabrutinib with rituximab.

Key Points

  • This study aims to evaluate the efficacy and safety of orelabrutinib combined with rituximab in treatment-naïve marginal zone lymphoma patients.
  • Multi-center, single-arm, prospective phase II clinical trial
  • Enrolled treatment-naïve patients with marginal zone lymphoma
  • Patients received orelabrutinib and rituximab for induction and maintenance phases
  • Overall response rate was 81.8% with a complete response rate of 72.7%
  • Disease progression occurred in 2 patients
  • Treatment-related adverse events included hematologic toxicities in 7 patients

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da1ahttps://doi.org/10.1182/blood-2025-3580
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.2026
  2. 2Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma2026 · 1 citations
  3. 3Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  4. 4Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations
  5. 5Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025